Melinta Therapeutic has entered into a $30 million growth capital debt financing agreement with Hercules Technology Growth Capital.

“This transaction provides Melinta with flexible working capital to support our ongoing clinical development of delafloxacin, which has completed one Phase 3 trial … . In addition, proceeds will support our early stage ESKAPE Pathogen Program, which we expect to yield one or more lead compounds in the next several months,” explained Mary Szela, chief executive officer of Melinta.